BOSTON IMMUNE TECHNOLOGIES & THERAPEUTICS
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
BOSTON IMMUNE TECHNOLOGIES & THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2011-01-01
Address:
Winchester, Virginia, United States
Country:
United States
Website Url:
http://www.bostonimmunetech.com
Total Employee:
1+
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
SPF Content Delivery Network Font Awesome Microsoft Exchange Online Office 365 Mail IPv6 BootstrapCDN Cloudflare Hosting Cloudflare DNS
Current Advisors List
Current Employees Featured
Founder
![]()
Investors List
BeiGene
BeiGene investment in Series A - Boston Immune Technologies & Therapeutics
![]()
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Boston Immune Technologies & Therapeutics
Official Site Inspections
http://www.bostonimmunetech.com Semrush global rank: 5.42 M Semrush visits lastest month: 1.56 K
- Host name: 186.27.212.35.bc.googleusercontent.com
- IP address: 35.212.27.186
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York

More informations about "Boston Immune Technologies & Therapeutics"
Boston Immune Technologies and Therapeutics | LinkedIn
Boston Immune Technologies and Therapeutics Biotechnology Research Boston, …See details»
Boston Immune Technologies & Therapeutics - Crunchbase
View contacts for Boston Immune Technologies & Therapeutics to access new leads and …See details»
BITT | Boston Immune Technologies & Therapeutics
Order cheap Hydrochlorothiazide High Blood Pressure cheap no prescription Discuss the risks …See details»
Boston Immune Technologies and Therapeutics, Inc.
Website: https://www.bostonimmunetech.com. Develops a proprietary discovery platform for …See details»
Boston Immune Technologies & Therapeutics, Inc.: Drug pipelines ...
Jun 21, 2023 Explore Boston Immune Technologies & Therapeutics, Inc. with its drug …See details»
Boston Immune Technologies & Therapeutics Inc · Boston Immune ...
BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. (doing business as …See details»
Boston Immune Technologies & Therapeutics - Craft
Boston Immune Technologies & Therapeutics $10 m in total funding,. See insights on Boston …See details»
Boston Immune Technologies and Therapeutics - ZoomInfo
Aug 18, 2023 BITT To Present Update on CD40 Program at AAI 2023 BOSTON--(BUSINESS …See details»
Media | BITT - Boston Immune Tech
August 16, 2024 BITT Announced CD40 Otsuka Research and Exclusivity Agreement and …See details»
Boston Immune Technologies and Therapeutics, Inc.
Oct 29, 2017 www.bostonimmunetech.com : disclaimers Any reproduction or further …See details»
BITT Announced CD40 Otsuka Research and Exclusivity Agreement …
Aug 16, 2024 BITT has begun clinical trials for BIR2101, its lead candidate, which is a …See details»
Boston Immune Technologies and Therapeutics and BeiGene Enter …
Feb 17, 2021 Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan …See details»
BITT Announced CD40 Otsuka Research and Exclusivity Agreement …
Aug 16, 2024 Learn more at: www.bostonimmunetech.com. Contacts. Karl Schmieder …See details»
BITT Announces NIH SBIR Award and New Board Member
Dec 13, 2021 BITT has received a SBIR grant from the National Cancer Institute at the US …See details»
BITT Announces NIH Award for Advancement of Anti-CD40 Antibody
Aug 31, 2023 Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage …See details»
Boston Immune Technologies and Therapeutics Raises $10M …
Mar 17, 2021 For more information, visit our website at www.bostonimmunetech.com. …See details»
Science | BITT - Boston Immune Tech
Science. would like to process and share personal data (e.g., mobile ad id) and data about …See details»
Selexis and Boston Immune Technologies and Therapeutics (BITT) …
Mar 9, 2021 GENEVA & BOSTON--(BUSINESS WIRE)--Mar 9, 2021-- Selexis SA and …See details»
Boston Immune Technologies and Therapeutics and BeiGene Enter …
Feb 17, 2021 For more information, visit our website at www.bostonimmunetech.com. About …See details»
Russell LaMontagne - President & Chief Executive Officer at …
Oct 19, 2024 Russell LaMontagne contact details: Email address: …See details»